Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    17327409 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: Eltrombopag and dexamethasone

Indicates status has not been verified in more than two years